Navigation

Wednesday, June 2, 2010

GO-LONG

Current fiscal will be a tremendous year for Indian biotech industry. Global recovery has stimulated Indian bitotech industry in 2009-10 and it is apparent from 52% growth in revenue. Among them Cipla can be a good buy both on fundamental and technical front.
Cipla is a prominent Indian pharma company for manufacturing low cost anti-AIDS drugs for HIV patients in developing countries.
Resently Cipla has formed a wholly owned subsidiary 'Cipla Singapore' in Singapore which will aid logistic and distribution of compnay's export business.






















Price Information
Open 323.00
High 327.95
Low 322.20
Last Price 325.10
Prev. Close 324.00
Close Price 324.75
Change 1.10
% Change 0.34
Total traded quantity 1282374
Turnover in Rs.Lakhs 4171.82


OI call option @ 340=8750
OI put option @300 =5000

We can expect and anticipate a profit of Rs.10 in coming days and Rs. 40 in a month. I consider Cipla a good buy.

1 comment: